Clinical development of hepatitis C virus host-targeting agents. - Test2 - elhamkhani - TriplyDB

Clinical development of hepatitis C virus host-targeting agents.

Clinical development of hepatitis C virus host-targeting agents.

http://www.wikidata.org/entity/Q37662513

about

Clinical development of hepatitis C virus host-targeting agents.

http://www.wikidata.org/entity/Q37662513

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical development of hepatitis C virus host-targeting agents.

@en

Clinical development of hepatitis C virus host-targeting agents.

@nl

type

label

Clinical development of hepatitis C virus host-targeting agents.

@en

Clinical development of hepatitis C virus host-targeting agents.

@nl

prefLabel

Clinical development of hepatitis C virus host-targeting agents.

@en

Clinical development of hepatitis C virus host-targeting agents.

@nl

P1433

Q37662513-B08C6330-E112-4E35-B2F2-D2E0BA4FF666

P1476

Q37662513-4AFEAF53-8CA5-4EE7-B11F-F0300D4A3282

P2093

Q37662513-094100B8-6B1A-46A4-993B-D3C9E9FEB7BC

P2860

Q37662513-170113AE-CDBD-45EB-83F9-E74CEB0A0888

Q37662513-197347DE-FF8D-4F7E-879E-BBAA8AF0EEC3

Q37662513-43C8FF4C-4615-4568-8A97-070542C2D7DD

Q37662513-6D43E17F-6FEB-4673-B659-D34430FCC560

Q37662513-6E98C11F-D168-462E-ADA9-51CCB85802DA

Q37662513-7BCD5EF5-AA23-4067-B662-06BF50593DC2

Q37662513-7D732D3C-C41B-4E30-AF9F-AB75ED8DFF71

Q37662513-82D370F9-29FD-43B8-BC0D-7EAD1DB90111

Q37662513-C0BF3823-18E8-40DC-9850-4A724888B82B

Q37662513-FA88F6B7-43A4-4801-AFFB-DF9474DFE6E3

P304

Q37662513-74FF419A-B2B9-47C2-8451-67438FF54AA0

P31

Q37662513-C9E42BB9-B6A6-4114-A861-53C5CB1F13AA

P356

Q37662513-9E935751-DBC7-4F2B-BD4D-F1B9ED1F0F6F

P407

Q37662513-FB374F43-8547-4FF1-AFC3-16EBD461045A

P433

Q37662513-00BF586C-F435-4A17-82EE-8F2E0EBE8434

P478

Q37662513-EE6EDB32-6535-46CA-A17C-B99136673897

P50

Q37662513-61E1DAC9-0692-4F30-A598-AD59C73D7C51

P577

Q37662513-41C76D23-C37E-47B8-ACBF-41DAC29C0523

P698

Q37662513-C0ED816B-B4F4-4DEF-8196-D4DD3B399ABD

P932

Q37662513-53DAC062-9C59-46AF-B494-0F72A4B0CCF4

P356

S0140-6736(17)30043-0

P1433

P1476

Clinical development of hepatitis C virus host-targeting agents

@en

P2093

Thomas F Baumert

http://www.w3.org/2001/XMLSchema#string

P2860

Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection

Treatment of HCV infection by targeting microRNA

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody

Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.

miR-122--a key factor and therapeutic target in liver disease.

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.

In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.

Curing chronic hepatitis C--the arc of a medical triumph.

Hepatitis C Drugs: Is Next Generation the Last Generation?

P304

674-675

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(17)30043-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

10070

http://www.w3.org/2001/XMLSchema#string

P478

389

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28087068

http://www.w3.org/2001/XMLSchema#string

P932

5323320

http://www.w3.org/2001/XMLSchema#string